Exactly.
What you have to find is common interest to go out there. What we've been able to do is attract the pharmaceutical industry. They paid $100 million to us to go into the unknown and not patent anything because it's the carrot that will allow academics to go work on the unknown. In large part, we would go there if there was the funding, if there was a mechanism to fund work in the unknown, but the way we allocate funding is by peer review, which is pretty conservative. I believe there's a huge appetite in the pharmaceutical industry, which spends about $30 billion globally on R and D, to spend money in basic research in the right areas.